Literature DB >> 29705354

Effect of TET2 on the pathogenesis of diabetic nephropathy through activation of transforming growth factor β1 expression via DNA demethylation.

Liling Yang1, Qian Zhang2, Qiong Wu2, Yi Wei2, Jiawei Yu2, Jiao Mu2, Jun Zhang2, Wei Zeng2, Bing Feng3.   

Abstract

AIMS: Transforming growth factor β1 (TGFβ1) plays a pivotal role in the pathogenesis of diabetic nephropathy (DN). However, the mechanism of its expression and activation induced by high glucose (HG) is still unclear. We mainly explored the role of ten-eleven translocation enzyme-2 (TET2) in regulating TGFβ1 expression in the process of DN. MAIN
METHODS: Human mesangial cells (HMCs) and db/db mice were used to analyze the biological effects of hyperglycemia both in vivo and in vitro. Gene expression levels, cell proliferation, protein recruitment levels to TGFβ1 regulatory region, DNA methylation statues and pathological changes in kidney were tested in different groups. Short hairpin RNA(shRNA) and oral inhibitor were used to knock down or inhibit TET2 expression. KEY
FINDINGS: Our study demonstrated that TET2 expression was increased in the renal cortex of db/db mice and in HMCs inducing by HG. We also found that TET2 binding was increased while DNA methylation of CpG islands was reduced in the TGFβ1 regulation region in HG, resulting in the increased expression level of TGFβ1 and cell phenotype transformation. More importantly, clinical research revealed that gradually decreased DNA methylation in the TGFβ1 regulatory region was also present in patients with diabetes and DN. SIGNIFICANCE: Our work suggests that TET2 plays an important role in the pathogenesis of DN by activating TGFβ1 expression through demethylation of CpG islands in the TGFβ1 regulatory region. This may provide a potential new therapeutic target for DN.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DNA methylation; Diabetic nephropathy; Mesangial cells; Ten-eleven translocation-2 protein; Transforming growth factor beta-1

Mesh:

Substances:

Year:  2018        PMID: 29705354     DOI: 10.1016/j.lfs.2018.04.044

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  9 in total

Review 1.  Epigenetics and epigenomics in diabetic kidney disease and metabolic memory.

Authors:  Mitsuo Kato; Rama Natarajan
Journal:  Nat Rev Nephrol       Date:  2019-06       Impact factor: 28.314

2.  Assessment of the TGFB1 gene expression and methylation status of the promoter region in patients with colorectal cancer.

Authors:  Damian Wodziński; Agnieszka Wosiak; Jacek Pietrzak; Rafał Świechowski; Radzisław Kordek; Ewa Balcerczak
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

Review 3.  Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease.

Authors:  Julio M Martinez-Moreno; Miguel Fontecha-Barriuso; Diego Martin-Sanchez; Juan Guerrero-Mauvecin; Elena Goma-Garces; Beatriz Fernandez-Fernandez; Sol Carriazo; Maria D Sanchez-Niño; Adrian M Ramos; Marta Ruiz-Ortega; Alberto Ortiz; Ana B Sanz
Journal:  Int J Mol Sci       Date:  2020-06-09       Impact factor: 5.923

4.  Ten-eleven translocation-2 affects the fate of cells and has therapeutic potential in digestive tumors.

Authors:  Feng Wang; Jing Zhang; Jian Qi
Journal:  Chronic Dis Transl Med       Date:  2020-01-08

Review 5.  Effects of metabolic memory on inflammation and fibrosis associated with diabetic kidney disease: an epigenetic perspective.

Authors:  Wen Zheng; Jia Guo; Zhang-Suo Liu
Journal:  Clin Epigenetics       Date:  2021-04-21       Impact factor: 6.551

6.  Reversal of the renal hyperglycemic memory in diabetic kidney disease by targeting sustained tubular p21 expression.

Authors:  Moh'd Mohanad Al-Dabet; Khurrum Shahzad; Ahmed Elwakiel; Alba Sulaj; Stefan Kopf; Fabian Bock; Ihsan Gadi; Silke Zimmermann; Rajiv Rana; Shruthi Krishnan; Dheerendra Gupta; Jayakumar Manoharan; Sameen Fatima; Sumra Nazir; Constantin Schwab; Ronny Baber; Markus Scholz; Robert Geffers; Peter Rene Mertens; Peter P Nawroth; John H Griffin; Maria Keller; Chris Dockendorff; Shrey Kohli; Berend Isermann
Journal:  Nat Commun       Date:  2022-08-27       Impact factor: 17.694

7.  Relationship between transforming growth factor-β1 and type 2 diabetic nephropathy risk in Chinese population.

Authors:  Tianbiao Zhou; Hong-Yan Li; Hongzhen Zhong; Zhiqing Zhong
Journal:  BMC Med Genet       Date:  2018-11-20       Impact factor: 2.103

Review 8.  The function and regulation of TET2 in innate immunity and inflammation.

Authors:  Boyi Cong; Qian Zhang; Xuetao Cao
Journal:  Protein Cell       Date:  2020-10-21       Impact factor: 14.870

Review 9.  The Potential Equivalents of TET2 Mutations.

Authors:  Sergiu Pasca; Ancuta Jurj; Mihnea Zdrenghea; Ciprian Tomuleasa
Journal:  Cancers (Basel)       Date:  2021-03-24       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.